Ganowa a Lokaci guda don Kamuwa da Tarin Fuka da MDR-TB

Tarin fuka (TB), wanda tarin fuka na Mycobacterium ke haifarwa(MTB), har yanzu yana zama barazana ga lafiyar duniyada kuma ƙaruwarjuriya ga maɓalliTBmagunguna kamar Rifampicinn (RIF) da Isoniazid (INH)yana da mahimmanci kamar yaddacikas ga ci gaban duniyaTB ƙoƙarin sarrafawa.Mai sauri da daidaitogwajin kwayoyin halittatarin fuka da kuma juriya ga RIF&WHO ta ba da shawarar INH don amfani da shiganomarasa lafiya da suka kamu da cutarkan lokacikumasamar musu da magani mai dacewa a cikin lokaci.

Kalubale

An kiyasta cewa mutane miliyan 10.6 ne suka kamu da cutarya kamu da cutar tarin fuka a shekarar 2022, wanda ya haifar daAn kiyasta mutuwar mutane miliyan 1.3, nesa da matakin shekarar 2025 na Tsarin Kare Tarin Fuka

Tarin fuka mai jure wa magani, musamman MDR-TB (mai jure wa RIF)&INH),yana ƙara yin tasiri ga tattalin arzikin duniya TB maganida kuma rigakafi.

Gano cutar tarin fuka da kuma juriyar RIF/INH cikin sauri a lokaci gudaana buƙatar gaggawa dona bayakumamagani mafi inganci idan aka kwatantatare dasakamakon gwajin juriyar magani.

NamuMafita

Marco & Micro-TestGano Tarin Fuka 3-a cikin 1 don kamuwa da cutar Tarin Fuka/Kwamfutar Gano Tarin Fuka da Rigakafi ta NIHyana ba da damar ingantaccen ganewar asaliTarin fuka da RIF/INH a cikin wani ganowa.

Fasahar Melting Curve tana gano tarin fuka da kuma tarin fuka a lokaci guda.

Gano tarin fuka/TB guda 3 a cikin 1 yana tabbatar da kamuwa da cutar tarin fuka da kuma juriyar magunguna masu mahimmanci (RIF/INH) yana ba da damar yin maganin tarin fuka cikin lokaci da kuma daidai.

Mycobacterium Tuberculosis Nucleic Acid da Rifampicin, Kayan Gano Juriya na Isoniazid (Narkewar Lanƙwasa)

Na yi nasarar gano gwajin tarin fuka sau uku (cutar tarin fuka, RIF & juriyar NIH) a cikin ganowa ɗaya!

Sakamako mai sauri: Akwai a cikin awanni 2-2.5 tare da fassarar sakamako ta atomatik yana rage horon fasaha don aiki;

Samfurin Gwaji: man shafawa, al'ada mai ƙarfi, al'adar ruwa

Babban Jin Daɗi: Kwayoyin cuta 25/mL ga tarin fuka, ƙwayoyin cuta 200/mL ga ƙwayoyin cuta masu juriya ga RIF, ƙwayoyin cuta 400/mL ga ƙwayoyin cuta masu juriya ga INH, yana tabbatar da ingantaccen ganowa koda a ƙananan nauyin ƙwayoyin cuta.

Manufofi Da Yawa: TB-IS6110; RIF-resistance-rpoB (507~503); INH-resistance-InhA, AhpC, katG 315;

Tabbatar da Inganci: Kulawa ta ciki don tabbatar da ingancin samfurin don rage rashin kyawun sakamako;

Yarjejeniya Mai Yaway: Daidaituwa da yawancin tsarin PCR na yau da kullun don samun damar dakin gwaje-gwaje (Bio-Rad CFX96, SLAN-96P/96S, Bioer Quantgene 9600);

Bin Dokokin WHO: Bin ƙa'idodin WHO game da kula da tarin fuka masu jure wa magunguna, tabbatar da aminci da dacewa a ayyukan asibiti.